Rivaroxaban Versus Enoxaparin As Thromboprophylaxis In Degenerative Spine Surgery .
Rivaroxaban versus enoxaparin as thromboprophylaxis in degenerative spine surgery: a randomized blinded non-inferiority study.
Eur Spine J . 2025 May;34(5):1926-1933.Two hundred twenty patients undergoing degenerative spine surgery were randomized to receive either enoxaparin 40 mg subcutaneously once daily (n=110) or rivaroxaban 10 mg orally once daily (n=110). The primary outcome was the incidence of venous thromboembolism (VTE) (DVT and PE). Secondary outcomes included reoperation rate, length of hospital stay, surgical site infection, CSF leakage, and other complications. Outcomes were assessed at 2 weeks and 3 months postoperatively. Overall, the results of the study revealed that rivaroxaban was non-inferior to enoxaparin for VTE prevention, with significantly lower reoperation rates and shorter hospital stays. These findings suggest that rivaroxaban may be a safe and effective alternative to enoxaparin for thromboprophylaxis in this setting.
Unlock the Full ACE Report
You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now
Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidencecontent for as little as $1.99 per week.
Already have an account? Log in
0 of 4 monthly FREE articles unlocked
